Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

PURPOSE: To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer. METHODS: This prospective, observational time, and motion stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., De la Haba-Rodríguez, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700215/
https://www.ncbi.nlm.nih.gov/pubmed/28577152
http://dx.doi.org/10.1007/s12094-017-1684-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700215/
https://www.ncbi.nlm.nih.gov/pubmed/28577152
http://dx.doi.org/10.1007/s12094-017-1684-4

Ejemplares similares